<html><head></head><body><h1>Ipratropium (Oral Inhalation)</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(i pra TROE pee um)</p><h2>Index Terms</h2><ul><li>Ipratropium Bromide</li></ul><h2>Dosage Forms</h2><p>Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p><p>Aerosol Solution, Inhalation, as bromide: </p><p>Atrovent HFA: 17 mcg/actuation (12.9 g)</p><p>Solution, Inhalation, as bromide: </p><p>Generic: 0.02% (2.5 mL)</p><p>Solution, Inhalation, as bromide [preservative free]: </p><p>Generic: 0.02% (2.5 mL)</p><h2>Brand Names: U.S.</h2><ul><li>Atrovent HFA</li></ul><h2>Pharmacologic Category</h2><ul><li>Anticholinergic Agent</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.</p><h3>Absorption</h3><p>Not readily absorbed into the systemic circulation from the surface of the lung or from the GI tract; ~7% absorbed after nebulization of a 2 mg dose</p><h3>Distribution</h3><p>15% of dose reaches the lower airways</p><h3>Metabolism</h3><p>Partially metabolized to inactive ester hydrolysis products</p><h3>Excretion</h3><p>Urine (50%)</p><h2>Onset of Action</h2><p>Bronchodilation: Within 15 minutes; Peak effect: 1 to 2 hours</p><h2>Duration of Action</h2><p>Metered-dose inhaler: 2 to 4 hours; Nebulization solution: 4 to 5 hours, up to 7 to 8 hours in some patients</p><h3>Half-Life Elimination</h3><p>2 hours</p><h3>Protein Binding</h3><p>≤9%</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p><b>Chronic obstructive pulmonary disease:</b> Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema</p><h2>Off Label Uses</h2><h3>Acute asthma (exacerbations)</h3><p>Controlled trials and a meta-analysis have demonstrated that the addition of ipratropium to short-acting beta-agonist (SABA) therapy in the management of moderate to severe acute asthma exacerbations has been associated with a decreased risk of hospitalization and an improvement in lung function <sup>[Griffiths 2013]</sup>, <sup>[Rodrigo 2000]</sup>.</p><p>Based on the National Heart, Lung, and Blood Institute/National Asthma Education and Prevention Program guidelines <sup>[NAEPP 2007]</sup> and the Global Initiative for Asthma guidelines, the use of ipratropium in combination with a SABA, such as albuterol, is an effective and recommended treatment in the management of patients with asthma exacerbation.</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to ipratropium, atropine (and its derivatives), or any component of the formulation</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Note: </b>In patients with coronavirus disease 2019 (COVID-19) who require bronchodilator therapy for asthma or chronic obstructive pulmonary disease symptoms, the use of pressurized metered-dose inhalers as opposed to nebulized delivery is preferred. Nebulized delivery may increase the transmission of particles (SARS-CoV2) into the environment and potentially decrease the expiratory circuit filter life (AARC 2020).</p><p><b>Chronic obstructive pulmonary disease:</b> Inhalation:</p><p>Metered-dose inhaler (MDI): 2 inhalations (34 mcg) 4 times daily; maximum dose: 12 inhalations (204 mcg)/day.</p><p>Nebulization solution: 0.5 mg (500 mcg, one unit-dose vial) every 6 to 8 hours.</p><p><b>Acute asthma (exacerbations) (off-label use):</b> Moderate to severe exacerbations:</p><p>Inhalation: <b>Note:</b> Should be given in combination with a short-acting beta-adrenergic agonist.</p><p>MDI: 8 inhalations (136 mcg) every 20 minutes as needed for up to 3 hours (NAEPP 2007).</p><p>Nebulization solution: 0.5 mg (500 mcg, one unit-dose vial) every 20 minutes for 3 doses, then as needed (NAEPP 2007).</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2>Dosing: Geriatric</h2><p>Refer to adult dosing.</p><h2>Dosing: Pediatric</h2><p><b>Note: </b>In patients with coronavirus disease 2019 (COVID-19) who require bronchodilator therapy for asthma symptoms, the use of pressurized metered-dose inhalers as opposed to nebulized delivery is preferred. Nebulized delivery may increase the transmission of particles (SARS-CoV2) into the environment and potentially decrease the expiratory circuit filter life (AARC 2020).</p><p><b>Asthma, acute exacerbation:</b> Limited data available (GINA 2018; NAEPP 2007): <b>Note: </b>For moderate to severe exacerbations, ipratropium may be considered if poor response to initial short-acting beta-2 agonist (SABA) therapy during initial management in an acute care setting (eg, emergency department). Ipratropium has not been shown to provide further benefit (eg, after first 24 hours) once the patient is hospitalized (GINA 2018; Vézina 2014):</p><p>Children:</p><p>Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 20 minutes for 1 hour (ie, 3 doses), then as needed; in trials, the usual reported dose is 0.25 mg (250 mcg) and reported interval range is every 1 to 8 hours typically with an increasing dosing interval as patient improves; some trials continued combination SABA/ipratropium therapy for duration of hospitalization (up to 49 hours) although trials have not demonstrated additional benefit with extended use (Vézina 2014)</p><p>Metered-dose inhaler: 4 to 8 puffs every 20 minutes as needed for up to 3 hours</p><p>Adolescents:</p><p>Nebulization: 0.5 mg (500 mcg) every 20 minutes for 3 doses, then as needed</p><p>Metered-dose inhaler: 8 puffs every 20 minutes as needed for up to 3 hours</p><p><b>Asthma, maintenance (nonacute):</b> Limited data available: <b>Note:</b> Evidence is lacking that ipratropium provides added benefit to beta-2 agonists in long-term control asthma therapy (GINA 2018; NAEPP 2007):</p><p>Children &lt;12 years:</p><p>Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 6 to 8 hours</p><p>Metered-dose inhaler: 1 to 2 inhalations every 6 hours; not to exceed 12 inhalations/day</p><p>Children ≥12 years and Adolescents:</p><p>Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 6 hours</p><p>Metered-dose inhaler: 2 to 3 inhalations every 6 hours; maximum daily dose: 12 inhalations/<b>day</b></p><p><b>Bronchospasm associated with chronic pulmonary conditions:</b> Children ≥12 years and Adolescents: Nebulization: 0.5 mg (500 mcg, one unit-dose vial) 3 to 4 times daily with doses 6 to 8 hours apart</p><p><b>Bronchospasm, wheezing:</b> Limited data available; efficacy results variable: Infants: Nebulization: 0.125 to 0.25 mg (125 to 250 mcg) every 4 hours has been found helpful in some infants with chronic or recurrent wheezing, and some patients with bronchiolitis; however, most bronchiolitis data suggests ipratropium is not effective (Hodges 1981; Prendiville 1987; Schuh 1992; Stokes 1983; Wang 1992).</p><p><b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p><h2>Administration</h2><p>For oral inhalation; avoid spraying in eyes.</p><p>Metered-dose inhaler: Prior to initial use, prime inhaler by releasing 2 test sprays into the air; inhaler does not require shaking. If the inhaler has not been used for &gt;3 days, reprime. Wash mouthpiece once a week for 30 seconds in warm water only and let air dry. Discard inhaler once dose indicator displays “0.”</p><p>Nebulization solution: Remove unit dose vial from foil pouch and squeeze contents into nebulizer reservoir; connect nebulizer to compressor. Breathe deeply and evenly until all medication has been inhaled; inhalation time is about 5 to 15 minutes. Clean nebulizer after use. Compatibility with other medications (eg, albuterol, budesonide) in nebulizer has been reported (Burchett 2010; Kamin 2014); also refer to institution-specific policies.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Metered-dose inhaler: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Exposure to temperatures &gt;48°C (120°F) may cause bursting. Do not puncture inhaler, throw into a fire or incinerator, or use or store near heat or open flame.</p><p>Nebulization solution: Store at 15°C to 30°C (59°F to 86°F). Protect from light. Store unused vials in foil pouch.</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Monitor therapy</i></p><p>Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Anticholinergic Agents: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergic Agents. <i> Avoid combination</i></p><p>Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Monitor therapy</i></p><p>Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Avoid combination</i></p><p>Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Avoid combination</i></p><p>Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Monitor therapy</i></p><p>Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Monitor therapy</i></p><p>Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Avoid combination</i></p><p>Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Monitor therapy</i></p><p>Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Avoid combination</i></p><p>Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Avoid combination</i></p><p>Methacholine: Ipratropium (Oral Inhalation) may diminish the therapeutic effect of Methacholine.  Management: Hold ipratropium for 12 hours before methacholine use.<i> Consider therapy modification</i></p><p>Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Monitor therapy</i></p><p>Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Monitor therapy</i></p><p>Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Monitor therapy</i></p><p>Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Monitor therapy</i></p><p>Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><p>Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Avoid combination</i></p><p>Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Avoid combination</i></p><p>Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Avoid combination</i></p><p>Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Monitor therapy</i></p><p>Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Avoid combination</i></p><p>Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Consider therapy modification</i></p><p>Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Monitor therapy</i></p><p>Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Avoid combination</i></p><p>Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Monitor therapy</i></p><p>Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Avoid combination</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>&gt;10%: Respiratory: Bronchitis (10% to 23%), exacerbation of chronic obstructive pulmonary disease (8% to 23%), sinusitis (1% to 11%)</p><p>1% to 10%:</p><p>Central nervous system: Headache (6% to 7%), dizziness (3%)</p><p>Gastrointestinal: Dyspepsia (1% to 5%), nausea (4%), xerostomia (2% to 4%), dysgeusia (1%)</p><p>Genitourinary: Urinary tract infection (2% to 10%)</p><p>Neuromuscular &amp; skeletal: Back pain (2% to 7%)</p><p>Respiratory: Dyspnea (7% to 8%), flu-like symptoms (4% to 8%), cough (&gt;3%), rhinitis (&gt;3%), upper respiratory tract infection (&gt;3%)</p><p>&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, acute eye pain, anaphylaxis, angioedema, blurred vision, bronchospasm, conjunctival hyperemia, constipation, corneal edema, decreased gastrointestinal motility, diarrhea, dry throat, glaucoma, hypersensitivity reaction, hypotension, increased intraocular pressure, laryngospasm, mouth edema, mydriasis, nausea, palpitations, pharyngeal edema, pruritus, skin rash, stomatitis, tachycardia, throat irritation, urinary retention, urticaria, visual halos around lights, vomiting</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• Bronchospasm: Paradoxical bronchospasm that may be life-threatening and may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue ipratropium and institute alternative therapy.</p><p>• CNS effects: May cause dizziness and blurred vision; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p><p>• Hypersensitivity reactions: Hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported. Discontinue therapy immediately if patient develops an allergic reaction.</p><p><b><i>Disease-related concerns:</i></b></p><p>• Glaucoma: Use with caution in patients with narrow-angle glaucoma; may increase intraocular pressure.</p><p>• Prostatic hyperplasia/bladder neck obstruction: Use with caution in patients with prostatic hyperplasia or bladder neck obstruction; may cause urinary retention.</p><p><b><i>Other warnings/precautions:</i></b></p><p>• Appropriate use: Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Only use in acute exacerbations of asthma in conjunction with short-acting beta-adrenergic agonists for acute episodes (NAEPP 2007).</p><h2>Monitoring Parameters</h2><p>FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; signs/symptoms of glaucoma; hypersensitivity reactions; urinary retention</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Considerations</h2><p>Systemic exposure following inhalation is negligible; maternal use is not expected to result in fetal exposure. Based on available information, an increased risk of adverse maternal or fetal outcomes has not been observed following use during pregnancy.</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to open the airways in lung diseases where spasm may cause breathing problems.</p><p>• This drug is not to be used to treat intense flare-ups of shortness of breath. Use a rescue inhaler. Talk with the doctor.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Back pain</p><p>• Headache</p><p>• Dry mouth</p><p>• Flu-like symptoms</p><p>• Nasal irritation</p><p>• Sore throat</p><p>• Stuffy nose</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain.</p><p>• Vision changes</p><p>• Eye pain</p><p>• Severe eye irritation</p><p>• Seeing halos or bright colors around lights</p><p>• Red eyes</p><p>• Trouble urinating</p><p>• Unable to pass urine</p><p>• Passing a lot of urine</p><p>• Severe dizziness</p><p>• Passing out</p><p>• Fast heartbeat</p><p>• Abnormal heartbeat</p><p>• Mouth sores</p><p>• Mouth irritation</p><p>• Trouble breathing</p><p>• Wheezing</p><p>• Cough</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive.  This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider.  For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about ipratropium</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>14 Reviews</li>
<li>Drug class: anticholinergic bronchodilators</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ipratropium Inhalation, oral/nebulization &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Ipratropium &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>COPD, Maintenance</li>
<li>Asthma</li>
<li>Bronchiectasis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>